Speciality European Pharma Limited

Quick facts

Phase 3 pipeline

• Goserelin plus Bicalutamide · Oncology
  Goserelin suppresses testosterone production via GnRH receptor agonism, while bicalutamide blocks androgen receptor signaling, providing dual hormonal suppression for androgen-dependent cancers.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Speciality European Pharma Limited portfolio CI brief
• Speciality European Pharma Limited pipeline updates RSS